The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Aegerion Pharmaceuticals Inc

Nasdaq: AEGR
Last

(U.S.) $2.49

Today's change0.00 0.00%
Updated September 28 7:15 AM EDT. Delayed by at least 15 minutes.
 

Aegerion Pharmaceuticals Inc

Nasdaq: AEGR
Last

(U.S.) $2.49

Today's change0.00 0.00%
Updated September 28 7:15 AM EDT. Delayed by at least 15 minutes.

Aegerion Pharmaceuticals Inc closed at (U.S.)$2.49.

Over the last five days, shares have gained 7.33%, but are down 75.35% for the last year to date. Shares have underperformed the S&P 500 by 98.09% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $2.49
  • High--
  • Low--
  • Bid / Ask(U.S.) $3.40 / (U.S.) $3.41
  • YTD % change-75.35%
  • Volume8,000
  • Average volume (10-day)897,067
  • Average volume (1-month)477,671
  • Average volume (3-month)640,723
  • 52-week range(U.S.) $1.23 to (U.S.) $16.63
  • Beta0.36
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$5.41
Updated September 28 7:15 AM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-80.76%

Aegerion Pharmaceuticals Inc has a net profit margin of -80.76%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.00%Sector:HealthcareIndustry:Pharmaceuticals - Diversified

Latest Company News

  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2016Q1/2016Q4/2015Q3/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015
Revenue45364967
Total other revenue--------
Total revenue45364967
Gross profit21213753
Total cost of revenue23151214
Total operating expense84957870
Selling / general / administrative40405444
Research & development11101111
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)102----
Other operating expenses, total028----
Operating income-39-59-29-2
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-47-65-36-9
Income after tax-47-66-37-10
Income tax, total0010
Net income-47-66-37-10
Total adjustments to net income--------
Net income before extra. items-47-66-37-10
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-47-66-37-10
Inc. avail. to common incl. extra. items-47-66-37-10
Diluted net income-47-66-37-10
Dilution adjustment--------
Diluted weighted average shares30292929
Diluted EPS excluding extraordinary itemsvalue per share-1.59-2.22-1.26-0.34
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share-1.37-2.19-1.26-0.34